Mar 11, 2020 / 03:45PM GMT
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research Analyst
Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech analysts at Barclays. It gives me a great pleasure to introduce Atara Biotherapeutics. With us today, we've got Pascal Touchon, the CEO of Atara.
Pascal, just maybe as an opening question before we get into Q&A. Perhaps you could give us a high-level introduction of the pipeline and the therapeutic focus and cash runway? Thank you.
Pascal Touchon - Atara Biotherapeutics, Inc. - President, CEO & Director
Thank you, Peter, and good morning, good afternoon, everyone. It's a pleasure to talk to you today. Atara Biotherapeutics is a leading company in the field of allogeneic off-the-shelf T-cell immunotherapy. We are not only a very advanced platform, but we have 4 key strategic priorities, assets that are -- 2 of them in the clinic and 2 in late preclinical stage. Our most advanced asset, tab-cel or tabelecleucel, is right now in Phase III in relapsed/refractory PTLD, and we
Atara Biotherapeutics Inc at Barclays Global Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers